Edwards Lifesciences CVP Daniel Lippis sells $54,168 in stock

Edwards Lifesciences Corp (EW) insider Daniel J. Lippis, the Chief Validation Officer for TAVR, sold 619 shares of the company's common stock on September 11, 2026, for a total value of $54,168. The sale price of $87.51 per share was higher than the current stock price of $84.37, while analysts suggest the shares are fairly valued at this level.

Simultaneously, Lippis bought 619 shares using employee stock options, acquiring them at an exercise price of $72.68 per share, totaling $44,988. Following these transactions, Lippis now holds 40,033.9103 shares of Edwards Lifesciences common stock. All share transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Lippis on February 13, 2026.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.